Int J Cancer Manag. 2021 November; 14(11):e114577. doi: 10.5812/ijcm.114577.

Published online 2021 November 29. **Research Article**

Assessment of Breast Cancer Immunohistochemical Properties with Demographics and Pathological Features; A Retrospective Study

Vahid Ariabod [1], Maryam Sohooli [2], Ramin Shekouhi [2] and Kiana Payan [1, *]

[1] Department of Pathology, Islamic Azad University of Medical Sciences, Mashhad, Iran
[2] Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

[*] *Corresponding author*: Department of Pathology, Islamic Azad University of Medical Sciences, Mashhad, Iran. Email: kianapayan@gmail.com

Received 2021 March 14; **Revised** 2021 November 06; **Accepted** 2021 November 06.

Abstract

Background: Breast cancer is considered the most common malignant disease in the female population. It is known as an emerging epidemy with a great burden on women's health, which can be associated with poor outcomes. Some factors including histological type, immunohistochemistry (IHC), tumor grade, and tumor size can have effects on breast cancer.
Objectives: This study aimed at assessing the effects of mentioned factors on IHC type of breast cancer.
Methods: This retrospective cross-sectional study was conducted on 142 patients, who were referred to one of the referral centers for breast cancer in Mashhad. Information including age, histological type, familial history, menopause status, tumor grade, tumor size, and IHC properties was collected from the patient's medical records. Allred score was used for reporting hormonal status. The data were analyzed by version 26 of SPSS software.
Results: The mean age of patient was 50.2 $\pm$ 12.7. The frequency of luminal A and luminal B type was calculated as 29.7 and 18.9%, respectively. In addition, triple-negative IHC type has a prevalence of 24.3% and HER2 had a prevalence of 27%. There were no significant differences between age (P = 0.34), familial history (P = 0.42), menopause (P = 0.36), histological type (invasive: P = 0.11, in situ: P = 0.45), and IHC properties. However, tumor diameter (P = 0.0001) and tumor grading (P = 0.002) had significant association with IHC properties.
Conclusions: Factors including tumor size and pathological grade can have effects on the gene expression properties of breast cancers. Luminal IHC type A is more common in breast cancer and is associated with better outcomes. However, age, histological type, familial history, and menopause status had no effects on the IHC properties of breast cancer.

Keywords: Breast Cancer, Immunohistochemical Study, Tumor Pathology

1. Background

Breast cancer is defined as the malignant proliferation of epithelial cells that cover the ducts or lobules of the breast (1, 2). It is among the top third most common malignant diseases in the majority of populations. It is considered the most common invasive malignancy among women, which can impose a great burden on the female population globally (3, 4). The incidence and prevalence of breast cancer have been rising during the last decades with the estimation of more than 1 million new cases diagnosed annually (5). However, the 5-year survival rate of patients with breast cancer has been improved to 83.4 to 98.4% in localized forms and 23.3% in metastatic breast cancer, which may contribute to the development of well-established screening programs (6).

Accordingly, several risk factors have been introduced that are associated with the emergence of breast cancer in the female population including age, hormonal factors, genetic predisposition, familial history, and nutritional factors (7-9). Immunohistochemically, this heterogeneous tumor group could be classified into 4 intrinsic subtypes including luminal A, luminal B, human epidermal growth factor receptor 2 (HER2/neu) positive, and basal or triple-negative, which are associated with different prognosis and treatment strategies (10). Modern studies surveyed that the steroid hormone receptor expression on tumor cells could determine the course of the disease. For instance, the luminal subtype of breast cancer is associated with better prognostic features and survival. However, triple-negative tumors and HER2-positive breast cancer could manifest as more aggressive invasive tumors with unfavorable outcomes (11-13).

At present, there is not much evidence for the assessment of immunohistochemistry (IHC) properties of breast cancer and its clinical and biological features especially in

developing countries including Iran.

2. Objectives

This study aimed at investigating 4 IHC subtypes and comparing the association between pathological, demographics, and clinical behaviors of different IHC features of breast cancer.

3. Methods

3.1. Study Design

This retrospective cross-sectional study was conducted on female patients with breast cancer, who presented to Aria Hospital, Mashhad, Iran from 2012 to 2019. The patients who underwent surgery and had the pathological report in addition to the immunohistochemical properties in their medical records were included in the study. Furthermore, patients who had a history of neoadjuvant chemotherapy and patients who had pathologic species from other manners including fine-needle aspiration or core needle biopsy were excluded from the study. Convenience sampling method was used for patient selection and the study population was estimated to be at a minimum of 90 patients based on chi-squared (χ^2) test and power, which was assumed based on a similar study (14). Historically, the value of 0.05 has been used for type-I error (α). Accordingly, a type-I error (α) occurs when a null hypothesis is rejected and power is the probability of rejecting a false null hypothesis. Beta is the probability of a type-II error, which occurs when a false null hypothesis is not rejected. The sample size was calculated with the aid of PASS® software:

$$n = \delta_{\alpha,\beta}\left[\sum_{i=1}^{r}\sum_{j=1}^{c}\frac{(p_{ij}-p_{i.}\,p_{.j})^2}{p_{i.}p_{.j}}\right]^{-1}$$

Where,

$$X^2_{k-1}\left(X^2_{k-1}|\delta\right) = \beta$$

3.2. Data Collection

Patients' information including age, familial history of breast cancer, menopause status, histological type of breast cancer, immunohistochemical and hormonal properties of breast cancer, tumor grading, and size were collected from the medical records.

3.3. IHC Assessment

Patients with a history of breast cancer, who were confirmed with mammography and surgical pathology were assessed for immunohistochemistry properties. For the preparation of the species, a 0.4 millimeter of the species was extracted by a pathological needle puncture and separated with a thickness of one micrometer. The species were inserted on adhesion microscope slides and after wax deposition, the microscopic slides were hydrated by ethanol for 5 minutes. Antigen retrieval was performed with EDTA-TRIS solution (Sigma-Aldrich®, USA) at the temperature of 98° of centigrade for 20 minutes. After cooling down and washing with tris buffered saline (Sigma-Aldrich®, USA), species were inserted into hydrogen peroxide with 3% of concentration. For antibody incubation, species were washed 30 minutes with antibodies, and a post-primary block solution was used for 20 minutes. For the last step, after washing species with tris buffered saline (TBS) for the second time, microscopic slides were incubated with Novolink™ polymer for 20 minutes. Prepared slides were seen by a light microscope. The last guideline of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) was used for reporting immunohistochemical results. All IHC samples were analyzed and commented on by 2 board-certified breast cancer pathologists.

3.4. Hormonal Receptor Assessment

Allred score was used for reporting the hormone receptors (15). PharmxDX kit (Agilent®, Dako, USA) was used for estrogen and progesterone hormonal assessment. Percentage score (PS) and intensity score (IS), which are two indicators of Allred score and suggest the proportion of colored cells, were used for hormonal assessment.

3.5. Statistical Analysis

Before starting the statistical analysis, the Kolmogorov-Smirnov test was used for evaluating the normality of data. Considering the lack of normality in data, the Mann-Whitney test and Kruskal-Wallis test were used for comparing the quantitative variables. Furthermore, the chi-square test and exact fisher test were used for analyzing qualitative data. A P-value below 0.05 is considered significant.

4. Results

4.1. Demographics

A total of 142 female patients were included in the final analysis. The mean age of the patient was 50.2 $\pm$ 12.7 (range: 20 - 75). The results of demographics and pathological features of patients are demonstrated in Table 1.

Table 1. Study Variables

Variables	No. (%)
Age range	
< 40	24 (16.2)
40 - 50	49 (34.2)
> 50	69 (49.6)
Family history	
Positive	78 (54.9)
Negative	64 (45.1)
Menopause	
Positive	76 (53.5)
Negative	66 (46.5)
Immunohistochemical properties	
Luminal A	57 (29.7)
Luminal B	28 (18.9)
Triple-negative	27 (24.3)
Overexpression of HER2/NEU	30 (27)
Invasive histologic type	
Invasive ductal carcinoma	97 (87.3)
Invasive lobular carcinoma	8 (7.2)
Invasive medullary carcinoma	2 (1.8)
Invasive tubular carcinoma	4 (3.6)
In situ histologic type	
Ductal carcinoma in situ	28 (90.4)
Lobular carcinoma in situ	3 (9.6)
Tumor grade	
Grade 1	4 (3.1)
Grade 2	76 (53.6)
Grade 3	62 (43.3)
Tumor diameter	
T_1	17 (11.9)
T_2	94 (66.2)
T_3	21 (14.8)
T_4	10 (7.1)

4.2. IHC Properties

In the assessment of IHC properties, luminal A molecular type had the most frequency (29.7%). The disturbances of IHC type of breast cancers and study variables are demonstrated in Table 2. As seen in Table 2, variables including age (P = 0.34), familial history (P = 0.42), menopause (P = 0.36), and histological type (invasive: P = 0.11, in situ: P = 0.45) did not have any relationship with IHC properties of breast cancer. However, tumor diameter (P < 0.001) and tumor grading (P = 0.001) are significantly related to the IHC properties.

Accordingly, the Kruskal-Wallis test showed a significant difference between IHC type and tumor grade. According to the result, tumor grade was higher in both triple-negative and HER2/NEU IHC subtypes. Also, in terms of tumor diameter, the results showed a significant difference between IHC type and tumor diameter. Tumor diameter was higher in both triple-negative and HER2/NEU. However, both tumor grade and diameter were accordingly lower in luminal A IHC type (Table 2). Invasive ductal carcinoma is the most common type of invasive cancer. In addition, the most common type of IHC property observed in invasive ductal carcinomas was the overexpression of HER2/NEU. In addition, luminal A type was more prevalent among other types of breast cancer. However, this difference was not statistically significant (P = 0.119).

The relationship between medical information (age, histological type, familial history, menopause status, tumor grade, tumor diameter) and IHC type was studied by stepwise multinomial logistic regression by using medical information as independent factors and IHC as a dependent factor. Then, only significant independent factors were retained in the final regression model (Table 3). Therefore, the only variable, tumor diameter, was associated with IHC type in the presence of the other factors (P = 0.001).

5. Discussion

In this study, it was demonstrated that tumor size and tumor grading are two main factors affecting the IHC properties of breast cancer cells. Greater breast tumors and high-grade cancers are associated with unfavorable IHC properties such as the lack of hormonal receptors (triple-negative) or the lack of estrogen and progesterone receptors.

Breast cancer is the most common malignant neoplasm among women, which has a 5-year survival rate between 27 and 90% based on time of diagnosis, metastasis, epidemiology, and cancer subtype (16-18). In the study of Abedi et al., the 5-year survival rate of patients with breast cancer was 69.5% (19). In addition, Baghestani et al. concluded a 95% rate of 1-year survival, followed by a 79% 5-year survival, and a 50% 10-year survival rate among Iranian women diagnosed with breast cancer (20). Furthermore, several factors can affect the patient's survival including age, IHC type, histological type, and familial history (21). That said, molecular prognostic factors and hormonal factors assessed by IHC are at the center of attention nowadays (22).

Table 2. The Disturbances of Immunohistochemistry Type of Breast Cancers and Study Variables [a]

Variables	Immunohistochemical Type				P-Value
	Triple-Negative	Luminal A	Luminal B	HER2/NEU	
Age range					0.34 [b]
< 40	2 (8.2)	8 (33.4)	8 (33.4)	6 (25)	
40 - 50	12 (24.5)	20 (40.8)	8 (16.3)	9 (18.4)	
> 50	13 (18.8)	29 (42)	10 (14.5)	17 (24.7)	
Family history					0.42 [c]
Positive	20 (25.6)	24 (30.7)	12 (15.4)	22 (28.3)	
Negative	13 (20.3)	21 (32.8)	12 (18.7)	18 (28.2)	
Menopause					0.36 [c]
Positive	19 (25)	23 (30.2)	13 (17.1)	21 (27.7)	
Negative	14 (21.2)	20 (30.3)	13 (19.7)	19 (28.8)	
Invasive histologic type					0.11 [b]
Invasive ductal carcinoma	26 (26.8)	25 (25.8)	17 (17.5)	29 (29.9)	
Invasive lobular carcinoma	1 (12.5)	4 (50)	3 (37.5)	0 (0)	
Invasive medullary carcinoma	0 (0)	2 (100)	0 (0)	0 (0)	
Invasive tubular carcinoma	0 (0)	2 (50)	1 (25)	1 (25)	
In situ histologic type					0.45 [b]
Ductal carcinoma in situ	0 (0)	21 (75)	7 (25)	0 (0)	
Lobular carcinoma in situ	0 (0)	3 (100)	0 (0)	0 (0)	
Tumor grade	2.69 ± 0.471	2.16 ± 0.554	2.12 ± 0.485	2.52 ± 0.509	0.001 [d]
Tumor diameter	3.63 ± 0.926	2.81 ± 0.480	3.07 ± 0.539	3.53 ± 0.681	< 0.001 [d]

[a] Values are expressed as No. (%) or mean ± SD.
[b] Exact fisher test.
[c] Chi-Square test.
[d] Kruskal-Wallis test.

IHC is used to distinguish surface proteins and antigens in different cells (23). In the IHC study, various specific markers are used to identify tumor subtypes and tissue origin, which are essential in the differentiation of primary tumors from the metastatic origin (24). Furthermore, IHC evaluations classify breast cancer cells based on their hormonal receptors (25). Estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor-2 (HER2), and Ki-67 are 4 common biomarkers for the IHC study of breast cancer (26, 27). Based on hormonal receptors, IHC properties of breast cancers are classified as triple-negative tumors (negative for ER, PR, and HER2), luminal A (positive for ER, positive/negative for PR, negative for HER2, and < 14% of Ki-67), luminal B (positive for ER, positive/negative for PR, negative for HER2, and ≥ 14% of Ki-67), and HER2 positive (negative for ER, negative for PR, positive for HER2, and ≥ 14% of Ki-67) (28).

In the current study, luminal A type was the most commonly diagnosed IHC type of breast cancer, which was in association with previous studies (28, 29). There was no significant association between IHC properties and histological type of breast cancer. However, most invasive and in situ carcinomas were luminal A-type. Gupta et al. demonstrated no significant differences between the type of breast cancer and IHC properties (30). In a study conducted by Rao et al., ductal carcinoma in situ was mostly HER2 positive, but this association was not statistically significant (31). In contrast, few studies observed contraindicatory results. In the study of Jalava et al., lobular carcinomas were more associated with higher expression of ER and PR (32). Moreover, Holloway et al. demonstrated that triple-negative IHC type is frequently associated with ductal carcinoma (33). It seems that further studies are needed to evaluate the association between histologic types of breast cancers and their IHC properties.

Tumor grade is considered one of the important factors affecting the prognosis and the survival of patients with breast cancer (34). In our study, IHC type had a signifi-

Table 3. Multinomial Logistic Regression by Using Medical Information as Independent Factors and IHC as A Dependent Factor

IHC Type (Dependent Variable) [a] and Independent Variable	Coefficient (B)	Std. Error	Wald	df	P-Value	Exp (B)
Luminal A						
Intercept	-19.711	7203.325	0.000	1	0.998	
Tumor diameter = T_1	21.097	7203.325	0.000	1	0.998	1452860761
Tumor diameter = T_2	20.067	7203.325	0.000	1	0.998	518878843
Tumor diameter = T_3	18.324	7203.325	0.000	1	0.998	90803797.6
Tumor diameter = T_4	0 [b]	-	-	0	-	-
Luminal B						
Intercept	-20.096	0.707	807.712	1	0.000	
Tumor diameter = T_1	20.096	1.581	161.542	1	0.000	534139968
Tumor diameter = T_2	19.942	0.809	607.372	1	0.000	457834258
Tumor diameter = T_3	20.096	0	-	1	-	534139968
Tumor diameter = T_4	0 [b]	-	-	0	-	-
HER2/NEU						
Intercept	-0.847	0.69	1.508	1	0.220	
Tumor diameter = T_1	-17.202	8306.049	0.000	1	0.998	3.38E-08
Tumor diameter = T_2	0.981	0.781	1.577	1	0.209	2.667
Tumor diameter = T_3	1.764	0.909	3.765	1	0.052	5.833
Tumor diameter = T_4	0 [b]	-	-	0	-	-

[a] The reference category: Triple-negative.
[b] This parameter is set to zero because it is redundant.

cant association with tumor grading. In the current study, grade 1 and grade 2 of breast cancers had luminal A as the highest IHC type. That said, the majority of high-grade tumor IHC types were diagnosed as triple-negative. In line with our study, Chand et al. stated that luminal A and luminal B IHC type had a significant correlation with age, tumor size, and tumor grade (22). Ayadi et al. suggested that the overexpression of HER2 is mostly associated with higher-grade breast cancer (35). Setyawati et al. concluded that low-grade breast cancers are related to luminal A IHC type. In addition, they concluded that high-grade cancers are mainly associated with luminal B and triple-negative IHC properties (36). All previous results were in line with the current study (37).

Tumor size is another important factor for breast cancer survival (38). Similar to previous studies, tumor size seems to affect the breast cancer IHC type (33, 36). Our study demonstrated that the majority of breast tumors with a mean size of 1-50mm were in the luminal group. Furthermore, tumor sizes of more than 50mm were associated with HER2 overexpression. Accordingly, a higher tumor diameter is associated with poor IHC properties.

This study has several limitations. Firstly, the present study is a retrospective cross-sectional study and not a prospective trial, which may increase the risk of potential selection and reporting bias. In addition, it can be argued that the present study may assess a few patients (n = 142). Therefore, we encourage physicians to evaluate the long-term oncological outcomes of patients with breast cancer with a larger sample population in a prospective design.

5.1. Conclusions

Factors including tumor size and pathological grade can affect the gene expression properties of breast cancers. Luminal IHC type A is more common in breast cancer and is associated with better outcomes. Age, histological type, familial history, and menopause status did not affect the IHC properties of breast cancer; although, further studies are needed to confirm these results.

Footnotes

Authors' Contribution: Study concept and design, K. P., and M. S.; Analysis and interpretation of data, R. S., and M. S.; Drafting of the manuscript, V. A. and R. S; Critical revision of the manuscript for important intellectual content, V. A. and K. P.; Statistical analysis, R. S.

Conflict of Interests: The authors declare no conflict of interest.

Data Reproducibility: All data generated or analyzed during this study are included in this published article.

Ethical Approval: The purpose of this research was completely explained to the patients and they were assured that their information will be kept confidential by the researchers. The present study was approved by the medical ethics committee of the academy. The permission was obtained from the Medical Ethics Committee of the Medical Faculty of Islamic Azad University of Mashhad (registration no: IR.IAU.MSHD.REC.1396.37).

Funding/Support: No funding was obtained for this study.

Informed Consent: Written informed consent was obtained from the patients for the publication of this article. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

References

1. Waks AG, Winer EP. Breast Cancer Treatment: A Review. *JAMA*. 2019;**321**(3):288–300. doi: 10.1001/jama.2018.19323. [PubMed: 30667505].
2. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. *Int J Biol Sci*. 2017;**13**(11):1387–97. doi: 10.7150/ijbs.21635. [PubMed: 29209143]. [PubMed Central: PMC5715522].
3. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. *Biol Res*. 2017;**50**(1):33. doi: 10.1186/s40659-017-0140-9. [PubMed: 28969709]. [PubMed Central: PMC5625777].
4. Mattiuzzi C, Lippi G. Current Cancer Epidemiology. *J Epidemiol Glob Health*. 2019;**9**(4):217–22. doi: 10.2991/jegh.k.191008.001. [PubMed: 31854162]. [PubMed Central: PMC7310786].
5. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. *Asian Pac J Cancer Prev*. 2016;**17**(S3):43–6. doi: 10.7314/apjcp.2016.17.s3.43. [PubMed: 27165206].
6. Tashiro H, Katabuchi H. The Relationship Between Estrogen and Genes in the Molecular Pathogenesis of Endometrial Carcinoma. *Curr Obstet Gynecol Rep*. 2014;**3**(1):9–17. doi: 10.1007/s13669-013-0074-3.
7. Zhang L, Huang Y, Feng Z, Wang X, Li H, Song F, et al. Comparison of breast cancer risk factors among molecular subtypes: A case-only study. *Cancer Med*. 2019;**8**(4):1882–92. doi: 10.1002/cam4.2012. [PubMed: 30761775]. [PubMed Central: PMC6488156].
8. Kaminska M, Ciszewski T, Lopacka-Szatan K, Miotla P, Staroslawska E. Breast cancer risk factors. *Prz Menopauzalny*. 2015;**14**(3):196–202. doi: 10.5114/pm.2015.54346. [PubMed: 26528110]. [PubMed Central: PMC4612558].
9. Escala-Garcia M, Morra A, Canisius S, Chang-Claude J, Kar S, Zheng W, et al. Breast cancer risk factors and their effects on survival: A Mendelian randomisation study. *BMC Med*. 2020;**18**(1):327. doi: 10.1186/s12916-020-01797-2. [PubMed: 33198768]. [PubMed Central: PMC7670589].
10. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol*. 2009;**27**(8):1160–7. doi: 10.1200/JCO.2008.18.1370. [PubMed: 19204204]. [PubMed Central: PMC2667820].
11. Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, Svintsitsky VS. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. *Exp Oncol*. 2009;**31**(1):48–51. [PubMed: 19300417].
12. Jarzabek K, Koda M, Walentowicz-Sadlecka M, Grabiec M, Laudanski P, Wolczynski S. Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology. *Tumour Biol*. 2013;**34**(6):4007–16. doi: 10.1007/s13277-013-0991-9. [PubMed: 23873111]. [PubMed Central: PMC3858613].
13. Fehm T, Maul H, Gebauer S, Scharf A, Baier P, Sohn C, et al. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor. *Strahlenther Onkol*. 2005;**181**(9):580–6. doi: 10.1007/s00066-005-1374-y. [PubMed: 16170485].
14. Nikhra P, Patel S, Taviad D, Chaudhary S. Study of ER (estrogen receptor), PR (Progesterone Receptor) and HER-2/NEU (Human epidermal growth factor receptor) expression by immunohistochemistry in breast carcinoma. *Int J Biomed Adv Res*. 2014;**5**:275–8.
15. Qureshi A, Pervez S. Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. *J Pak Med Assoc*. 2010;**60**(5):350–3. [PubMed: 20527604].
16. Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985-2016. *Breast*. 2017;**31**:46–50. doi: 10.1016/j.breast.2016.10.005. [PubMed: 27810699].
17. Fallahpour S, Navaneelan T, De P, Borgo A. Breast cancer survival by molecular subtype: A population-based analysis of cancer registry data. *CMAJ Open*. 2017;**5**(3):E734–9. doi: 10.9778/cmajo.20170030. [PubMed: 28951445]. [PubMed Central: PMC5621954].
18. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. *Cancer Epidemiol Biomarkers Prev*. 2018;**27**(6):619–26. doi: 10.1158/1055-9965.EPI-17-0627. [PubMed: 29593010].
19. Abedi G, Janbabai G, Moosazadeh M, Farshidi F, Amiri M, Khosravi A. Survival Rate of Breast Cancer in Iran: A Meta-Analysis. *Asian Pac J Cancer Prev*. 2016;**17**(10):4615–21. doi: 10.22034/apjcp.2016.17.10.4615. [PubMed: 27892673]. [PubMed Central: PMC5454606].
20. Baghestani AR, Zayeri F, Akbari ME, Shojaee L, Khadembashi N, Shahmirzalou P. Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center. *Asian Pac J Cancer Prev*. 2015;**16**(17):7923–7. doi: 10.7314/apjcp.2015.16.17.7923. [PubMed: 26625822].
21. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer (Dove Med Press)*. 2019;**11**:151–64. doi: 10.2147/BCTT.S176070. [PubMed: 31040712]. [PubMed Central: PMC6462164].
22. Chand P, Garg A, Singla V, Rani N. Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use. *Niger J Surg*. 2018;**24**(2):100–6. doi: 10.4103/njs.NJS_2_18. [PubMed: 30283220]. [PubMed Central: PMC6158994].
23. Buchwalow IB, Böcker W. *Immunohistochemistry: Basics and Methods*. 1st ed. Berlin, Heidelberg: Springer; 2010. doi: 10.1007/978-3-642-04609-4.
24. Schacht V, Kern JS. Basics of immunohistochemistry. *J Invest Dermatol*. 2015;**135**(3):1–4. doi: 10.1038/jid.2014.541. [PubMed: 25666678].
25. Zaha DC. Significance of immunohistochemistry in breast cancer. *World J Clin Oncol*. 2014;**5**(3):382–92. doi: 10.5306/wjco.v5.i3.382. [PubMed: 25114853]. [PubMed Central: PMC4127609].
26. Louie MC, Sevigny MB. Steroid hormone receptors as prognostic markers in breast cancer. *Am J Cancer Res*. 2017;**7**(8):1617–36. [PubMed: 28861319]. [PubMed Central: PMC5574935].
27. Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, et al. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. *Clin Med Insights Oncol*. 2014;**8**:107–11. doi: 10.4137/CMO.S18006. [PubMed: 25249766]. [PubMed Central: PMC4167319].
28. Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, et al. Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. *BMC Res*

Notes. 2012;**5**:376. doi: 10.1186/1756-0500-5-376. [PubMed: 22830453]. [PubMed Central: PMC3413599].
29. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst*. 2009;**101**(10):736–50. doi: 10.1093/jnci/djp082. [PubMed: 19436038]. [PubMed Central: PMC2684553].
30. Gupta D, Gupta V, Marwah N, Gill M, Gupta S, Gupta G, et al. Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors. *Iran J Pathol*. 2015;**10**(1):23–34. [PubMed: 26516322]. [PubMed Central: PMC4539786].
31. Rao C, Shetty J, Kishan Prasad HL. Morphological profile and receptor status in breast carcinoma: An institutional study. *J Cancer Res Ther*. 2013;**9**(1):44–9. doi: 10.4103/0973-1482.110358. [PubMed: 23575073].
32. Jalava P, Kuopio T, Huovinen R, Laine J, Collan Y. Immunohistochemical staining of estrogen and progesterone receptors: Aspects for evaluating positivity and defining the cutpoints. *Anticancer Res*. 2005;**25**(3c):2535–42. [PubMed: 16080489].
33. Holloway CMB, Jiang L, Whitehead M, Racz JM, Groome PA. Organized screening detects breast cancer at earlier stage regardless of molecular phenotype. *J Cancer Res Clin Oncol*. 2018;**144**(9):1769–75. doi: 10.1007/s00432-018-2687-4. [PubMed: 29909564].
34. Skoog P, Ohlsson M, Ferno M, Ryden L, Borrebaeck CAK, Wingren C. Tumor tissue protein signatures reflect histological grade of breast cancer. *PLoS One*. 2017;**12**(6). e0179775. doi: 10.1371/journal.pone.0179775. [PubMed: 28650989]. [PubMed Central: PMC5484475].
35. Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. *World J Surg Oncol*. 2008;**6**:112. doi: 10.1186/1477-7819-6-112. [PubMed: 18945339]. [PubMed Central: PMC2577672].
36. Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. *Asian Pac J Cancer Prev*. 2018;**19**(5):1263–8. doi: 10.22034/APJCP.2018.19.5.1263. [PubMed: 29801411]. [PubMed Central: PMC6031822].
37. Widodo I, Dwianingsih EK, Anwar SL, Fx Ediati T, Utoro T, Aryandono T, et al. Prognostic Value of Clinicopathological Factors for Indonesian Breast Carcinomas of Different Molecular Subtypes. *Asian Pac J Cancer Prev*. 2017;**18**(5):1251–6. doi: 10.22034/APJCP.2017.18.5.1251. [PubMed: 28610410]. [PubMed Central: PMC5555531].
38. Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer–a reappraisal. *Nat Rev Clin Oncol*. 2010;**7**(6):348–53. doi: 10.1038/nrclinonc.2010.39. [PubMed: 20309006].